医学
外科
腺瘤
不利影响
发育不良
多元分析
更安全的
切除术
病变
粘膜切除术
随机对照试验
析因分析
直肠
内科学
内窥镜检查
患者数据
临床试验
回顾性队列研究
前瞻性队列研究
靶病变
作者
Ingo Steinbrück,Timothy O'Sullivan,Óscar Nogales,Douglas Kevin Rex,Viktor Rempel,Cyrus R. Piraka,Oliver Cronin,Sheyla Montori,Christian Wiessner,Thomas Rösch,Eduardo Albéniz,Michael John Bourke,Heiko Pohl
出处
期刊:Gut
[BMJ]
日期:2026-09-15
卷期号:: gutjnl-2026
被引量:1
标识
DOI:10.1136/gutjnl-2026-339233
摘要
BACKGROUND: Cold resection is standard for small colorectal polyps and sessile serrated lesions (SSLs). For large (≥20 mm) non-pedunculated adenomas, it appears safer than hot snare endoscopic mucosal resection (EMR) but is associated with higher rates of residual/recurrent adenoma (RRA). OBJECTIVE: To pool individual patient data from all available randomised controlled trials (RCTs) and determine whether RRA differs across polyp subgroups. DESIGN: International, multicentre post hoc individual patient data meta-analysis of four RCTs. Primary outcomes were rates of major adverse events (AE) (AE=deep mural injury III-V/perforation and/or delayed bleeding) and RRA. Subgroup analyses assessed outcomes by location, size, morphology and histology. RESULTS: 1509 polyps in 1423 patients (mean age 66.1 years; mean size 31.3 mm) from 50 centres were included. Major AE occurred in 1.7% of cold versus 5.9% of hot snare resections (OR 0.26; p<0.001). Cold snare was the only factor to reduce major AE in multivariate analysis (OR 0.21; 95% CI 0.07 to 0.60; p=0.004). RRA was higher after cold resection (26.5% vs 12.8%; OR 2.61; p<0.001), with a significant interaction by lesion diameter (p=0.035). By histology, differences were the smallest in SSLs (15.0% vs 8.1%; OR 2.13; p=0.053) and greatest in adenomas with high-grade dysplasia (40.8% vs 18.0%; OR 2.88; p=0.002). CONCLUSIONS: Cold resection is safer than hot EMR but results in more than double the RRA in all adenoma subgroups, especially those with high-grade dysplasia. It may be appropriate for SSLs between 2 cm and 4 cm and selected cases under anticoagulant/antiplatelet therapy or multimorbid patients, for which further studies are needed.
科研通智能强力驱动
Strongly Powered by AbleSci AI